Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cardiovascular risk
Show results for

Refine by

Cardiovascular Risk Articles & Analysis

44 news found

Alfa Chemistry Expands into Marine Chemistry: A Dive into Marine Extracts, Oils, and Natural Products

Alfa Chemistry Expands into Marine Chemistry: A Dive into Marine Extracts, Oils, and Natural Products

Marine extracts deliver antioxidant benefits while providing anti-inflammatory and anti-aging properties which makes them essential for skincare products aimed at promoting joint health and cardiovascular function. Alfa Chemistry provides kelp and Fucus vesiculosus extracts which are recognized for their concentrated nutrients and therapeutic possibilities. ...

ByAlfa Chemistry


Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health risks including cardiovascular disease, kidney failure, and nerve damage. ...

ByAce Therapeutics


Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Unlock Functional Ingredient Benefits: Lecithin, Omega Fatty Acids, Phytosterol, Antioxidants at Alfa Chemistry

Such properties include anti-inflammatory effects, promotion of brain health, and reduction of cardiovascular risk. Regular intake has been demonstrated to reduce symptoms of depression and anxiety, enhance fetal brain development, and lower heart disease risks by managing cholesterol and blood pressure levels. ...

ByAlfa Chemistry


Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Creative Enzymes Unveils Semaglutide, a Promising Solution for Comprehensive Diabetes Management

Unlike traditional diabetes medications, Semaglutide has been shown to improve glycemic control, promote weight loss, and reduce the risk of cardiovascular events in individuals with type 2 diabetes. ...

ByCreative Enzymes


Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

Kerendia (finerenone) granted expanded indication in the EU for broad range of patients with chronic kidney disease and type 2 diabetes

The positive data from FIGARO-DKD demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D versus placebo. “Patients with chronic kidney disease are faced with an increased risk of cardiovascular events,” said Professor Peter Rossing, Head of ...

ByBayer AG


Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

Finerenone receives positive CHMP opinion for EU-label extension for broad range of patients with chronic kidney disease and type 2 diabetes

The study demonstrated that finerenone reduced the risk of cardiovascular events in a broad population of patients with stages 1-4 CKD and T2D. ...

ByBayer AG


Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors

” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. ...

ByGalapagos NV


Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

Kerendia (finerenone) receives updated label in the U.S. to include findings from Phase III FIGARO-DKD cardiovascular outcomes study

The positive data from the pivotal Phase III FIGARO-DKD study demonstrated that finerenone significantly reduced the risk of cardiovascular events in adult patients with CKD and T2D. Results from the trial were presented at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. ...

ByBayer AG


Online clinic Medon collaborates with Longenesis to develop a cardiovascular disease risk calculator

Online clinic Medon collaborates with Longenesis to develop a cardiovascular disease risk calculator

In order to increase the public awareness of cardiovascular health and encourage the population to take preventive action by identifying and mitigating the effects of cardiovascular disease (CVD) risk factors in a timely fashion, the online clinic Medon in collaboration with the health technology start-up Longenesis, has published a survey to ...

ByLongenesis


Major Biomedical Catalyst grant win

Major Biomedical Catalyst grant win

Dialysis treatment can reduce life expectancy by two thirds and almost half of patients die from cardiovascular complications, in part caused by the immune system reacting to components of the dialysis apparatus. ...

ByInvizius Limited


Second grant win to research Peritoneal Dialysis indication

Second grant win to research Peritoneal Dialysis indication

This suppresses the blood’s foreign body response preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular and other complications. Peritoneal Dialysis (PD) offers considerable benefits to patients but it has a high dropout rate, which has limited its adoption compared to Haemodialysis. ...

ByInvizius Limited


Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

Philippe Généreux, interventional cardiologist, commented, “We have been using the Early Bird in our clinical practice for the past two years, and the current design of incorporating a fully functional introducer sheath with bleed detection allows for seamless integration into high- risk interventional cardiovascular procedures. Embedding ...

BySaranas, Inc.


Bayer’s new treatment Kerendia (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes

Bayer’s new treatment Kerendia (finerenone) approved in EU for adult patients with chronic kidney disease associated with type 2 diabetes

“The approval of Kerendia offers physicians a new path to protect these vulnerable patients by reducing their risk of cardiovascular events and delaying kidney disease ...

ByBayer AG


BioXtreme and Advanced Medical Solutions s.r.o sign cooperation agreement in Czech Republic and Slovakia

BioXtreme and Advanced Medical Solutions s.r.o sign cooperation agreement in Czech Republic and Slovakia

About Advanced Medical Solutions s.r.o: Advanced Medical Solutions develops, produces, and distributes integrative solutions (devices, sw+ services) for the early and non-invasive diagnostics and therapy of arterial, venous and lymphatic systems with a specific focus on diabetic patients and other groups with cardiovascular risk factors. The aim is to prevent ...

ByBioXtreme Ltd.


oxLDL as a predictive marker

oxLDL as a predictive marker

Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart. Thus, the oxLDL/MDA Adduct ELISA of IDK® can not only detect particularly small, modified oxLDL particles (Pfützner A ...

ByImmundiagnostik AG


Nanox Announces Issuance of American Medical Association New Category III CPT® Code for Its Coronary Artery Calcium Population Health Solution

Nanox Announces Issuance of American Medical Association New Category III CPT® Code for Its Coronary Artery Calcium Population Health Solution

HealthCCSng can be incorporated into existing radiologist workflows, helping to identify and quantify CAC levels in their patients and stratify those patients based on their risk of cardiovascular disease and potential need for cardiac work up and treatment. ...

ByNano-X Imaging Ltd.


Nyxoah Provides General Corporate Update

Nyxoah Provides General Corporate Update

Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy ...

ByNyxoah SA


Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy ...

ByNyxoah SA


Nyxoah appoints new CFO

Nyxoah appoints new CFO

Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful ...

ByNyxoah SA


Orchestra BioMed Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT on Isolated Systolic Hypertension and Pulse Pressure

Orchestra BioMed Announces Presentations at TCT 2021 of Positive Long-Term Clinical Results from the MODERATO II Study Showing the Significant Clinical Impact of BackBeat CNT on Isolated Systolic Hypertension and Pulse Pressure

ISH is the predominant form of hypertension in patients over 60 years old and the most challenging to treat; elevated Pulse Pressure is a significant, independent risk factor of coronary heart disease. Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company focused on developing transformative therapeutic products ...

ByOrchestra BioMed, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT